XML 91 R76.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Reporting - Disclosure of Operating Segment Information (Detail) - AUD ($)
 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
Revenue      
License revenue $ 0 $ 0 $ 170,369
Other income      
Research material sales 119,089 191,721 84,018
Grant income 3,722,788 3,314,001 4,459,974
Net gain on fair value movement of warrants 0 131,896 591,070
Net gain on foreign exchange 113,458 623,511 1,228,122
Interest income 3,882,757 938,999 224,520
Total revenue and other income 7,838,092 5,200,128 6,758,073
Segment Result (42,716,625) (39,896,348) (32,210,792)
Profit/(loss) before income tax expense (42,716,625) (39,896,348) (32,210,792)
Income tax expense 0 0 (34) [1]
Loss after income tax expense (42,716,625) (39,896,348) (32,210,826)
Total segment assets 201,579,281 147,448,990 102,169,550
Total segment liabilities 12,057,539 10,979,601 8,092,184
Immunotherapy [Member]      
Revenue      
License revenue   0 170,369
Other income      
Research material sales 119,089 191,721 84,018
Grant income 3,722,788 3,314,001 4,459,974
Total revenue and other income 3,841,877 3,505,722 4,714,361
Segment Result (46,556,929) (41,431,305) (33,929,768)
Profit/(loss) before income tax expense (46,556,929) (41,431,305) (33,929,768)
Total segment assets 201,579,281 147,448,990 102,169,550
Total segment liabilities 12,057,539 10,979,601 8,092,184
Unallocated [member]      
Other income      
Net gain on fair value movement of warrants   131,896 591,070
Net gain on foreign exchange 113,458 623,511 1,228,122
Interest income 3,882,757 938,999 224,520
Total revenue and other income 3,996,215 1,694,406 2,043,712
Segment Result 3,840,304 1,534,957 (1,718,976)
Profit/(loss) before income tax expense $ 3,840,304 $ 1,534,957 $ (1,718,976)
[1] Income tax expense relates to tax payable for the Immutep subsidiary in the United States.